Response to Bell: industry perspective.
Baron
A D
AD
Amylin Pharmaceuticals Inc, San Diego, California 92121, USA. abaron@amylin.com
D001675:Bioethics; D002986:Clinical Trials as Topic / Q000592:standards*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004345:Drug Industry; D004992:Ethics, Medical; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
D007004:Hypoglycemic Agents